Bobby Muthalaly, MD
Nephrology · Tulsa, OKNPI 1457375586
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Travere Therapeutics, Inc. at 55.3% of the total. Reporting peaked in 2023 at $3,888 and has fallen 69.6% since, to $1,183 in 2025. Among nephrology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 292 payments — averaging $41.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$7K
- AstraZeneca$1K
- Amgen$607
- Otsuka America Pharmaceutical, Inc.$549
- Calliditas Therapeutics US Inc.$415
- Bayer$393
- plus $2K from 23 others
What the payments were for
- Consulting fees$5,20043%
- Travel & lodging$7977%
- Food & beverage$5,65747%
- Education$3963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 29 | $6,660 |
| AstraZeneca(2 entities) | 46 | $1,161 |
| Amgen(2 entities) | 44 | $607 |
| Otsuka America Pharmaceutical, Inc. | 24 | $549 |
| Calliditas Therapeutics US Inc. | 19 | $415 |
| Bayer | 23 | $393 |
| Novartis | 19 | $348 |
| Vifor Pharma, Inc. | 15 | $293 |
| OPKO Pharmaceuticals, LLC | 12 | $206 |
| Boehringer Ingelheim | 9 | $170 |
| Fresenius USA Marketing, Inc. | 9 | $170 |
| Daiichi Sankyo Inc. | 3 | $168 |
| Mallinckrodt Enterprises LLC | 4 | $127 |
| Ardelyx, Inc. | 6 | $122 |
| Akebia Therapeutics Inc | 6 | $100 |
| Merck | 4 | $87 |
| Mallinckrodt Hospital Products Inc. | 2 | $69 |
| Baxter Healthcare | 1 | $65 |
| Novo Nordisk | 2 | $53 |
| Apellis Pharmaceuticals, Inc. | 2 | $50 |
| Genentech USA, Inc. | 3 | $42 |
| GSK | 3 | $39 |
| Cormedix Inc. | 1 | $31 |
| Veloxis Pharmaceuticals, Inc. | 1 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INJECTAFER$122
- FARXIGA$110
- SOLIRIS$100
How this compares
$12,050 in reported general payments places this provider in the 90th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 34 | $140,338 |
| AuryxiaFerric Citrate | 26 | $42,336 |
| FarxigaDapagliflozin Propanediol | 23 | $19,731 |
| Sevelamer Carbonate | 76 | $11,363 |
| Cinacalcet Hcl | 44 | $8,167 |
| InvokanaCanagliflozin | 12 | $6,937 |
| Calcitriol | 312 | $5,568 |
| Mycophenolic AcidMycophenolate Sodium | 15 | $5,342 |
| Nifedipine ErNifedipine | 49 | $2,015 |
| Potassium Chloride | 48 | $1,313 |
| Torsemide | 65 | $1,286 |
| Tacrolimus | 13 | $1,260 |
| Nebivolol Hcl | 20 | $733 |
| Carvedilol | 64 | $663 |
| Losartan Potassium | 56 | $593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $170 | $140,33834 claims |
| Akebia Therapeutics IncAuryxia | $100 | $42,33626 claims |
| AstraZenecaFarxiga | $1,161 | $19,73123 claims |
| Johnson & JohnsonInvokana | $16 | $6,93712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Tulsa
- Sunil AgrawalTulsa$40K
- Pranay KathuriaTulsa$21K
- Kevin FuTulsa$14K
- Diptesh GuptaTulsa$13K
- Janet RussellTulsa$12K
- Narottam RegmiTulsa$12K
- Alpana PasrichaTulsa$9K
- Reza AzadiTulsa$9K
- Christine WilsonTulsa$8K
- Kusum BhandariTulsa$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.